$SOXL
With price aggressively slicing through the prior 152.50 Wall and pressing into the highs-153s, order flow is entirely dictated by unhedged dealer chasing. Treat any orderly pullback that holds above the 152.00 handle as a high-velocity continuation entry.
Stop your loss below 150.50 (a drop back through the breakout zone invalidates the immediate expansion).
$CRWV Major Update 🚨
JPMorgan today updated its stance on CoreWeave:
Rating: Neutral → Overweight
Price Target: $120 → $125
Key figures to watch:
• Product pricing adjusted by ~25% in July
• New contracts signed in Q3 valued at ~$40M/MW
• Contracted power capacity increased from 3.1 GW (projected for end-of-2025) to 4.2 GW as of August 11
• JPMorgan believes higher compute pricing will drive improvements in revenue and margins
What truly matters in the AI boom may not just be GPU sales volume.
It is about who owns the compute power and who holds pricing power.
$INFQ
Infleqtion's announcement demonstrates that neutral-atom platforms can achieve nearly the same ultra-dense error-correction efficiency (~2.67:1) on a system architecture that is fundamentally much easier to scale physically to hundreds and thousands of qubits without running out of physical room on a trap chip
$BWET anyone who is bullish thinking BWET can go back to $900 is gonna be rugpulled. Look at how much BWET was a few weeks ago and 2 weeks ago. This thing was $123. This bubble could go to $800 and in a day it showed us how it can dropped by $150. I believe this is going to be $500 and lower.
$SPCX SpaceXAI's Grok Bot AI agent reaches over 400,000 weekly users, Bloomberg says
SpaceXAI's Grok Bot AI agent has reached over 400,000 weekly users within a month of launching, Edward Ludlow of Bloomberg reports. By September 14, the Grok Bot hit 418,000 users, which was up 24% from the week prior, according to a presentation viewed by Bloomberg.
$VKTX
Dr Aronne regarding VK2735 — “Right in the range of the most competitive compounds out there” and “the rapid titration speaks to the tolerability”.
VK2735 weight-loss @ 33 weeks matched Tirzepatide @ 72 weeks and maintenance tolerability was similar to placebo.
This is a BIC medication
$ONDS This is a quick chart of where we are. Above the solid white trend line, and below the white line or wedge. Many formations occur in between that area . Remember , we closed up last week first time after 4 weeks of being down. Right now we are in a mini wedge, green trend line, on top of that red trend line. By Thursday around 7:30 am, this breaks out one way, up or down. This could happen any time but that wedge ends by then. We did trade to the 20 day ema- white horizontal lines. And as it should got rejected. The ema's matter, I won't trade down here. I will wait to the 50 day ema, roughly at the red dashed line above that . Patience
$ONDS This is a quick chart of where we are. Above the solid white trend line, and below the white line or wedge. Many formations occur in between that area . Remember , we closed up last week first time after 4 weeks of being down. Right now we are in a mini wedge, green trend line, on top of that red trend line. By Thursday around 7:30 am, this breaks out one way, up or down. This could happen any time but that wedge ends by then. We did trade to the 20 day ema- white horizontal lines. And as it should got rejected. The ema's matter, I won't trade down here. I will wait to the 50 day ema, roughly at the red dashed line above that . Patience
$BYND A federal judge just slashed trademark damages from $23.5M down to just $37,500! Considering it had roughly $38.9M in litigation liabilities already accrued on the books, clearing this massive overhang is almost like freeing up half a quarter’s revenue in straight balance sheet relief.
$PLTR Elliott’s calling for more bull. Don’t believe in this ticker, and extended PE rug pull always a threat. Target to short was $185-188 will be patient
$NVO Heavily undervalued with a lot of upside potential, sell/short at your own risk.
CagriSema FDA approval expected in Q4 will rip stock price upwards.
$VKTX That is $PFE $10 B drug performance at wk 28 wt loss (12% despite wkly doses and flattening of curve vs 22% at $VKTX 33 wks ) and look at vomit rate in the monthly maintenance in vesper 1 after wk 28
The most bullish part of the AI story?
Demand keeps expanding every time new compute comes online.
The biggest constraints are now HBM + chips + power + data centers.
$IREN is exposed to exactly this supply squeeze. 🚀